Bayer launched its drug finerenone to treat chronic kidney disease (CKD) associated with type-2 diabetes in India on Thursday. The drug, touted as a potential blockbuster drug for the German pharmaceutical firm, will be sold under the brand name Kerendia in India.

KERENDIA is a once-daily tablet that is proven to slow the progression of kidney damage and reduce the risk of cardiovascular death, heart attack, and hospitalization for heart failure in adults with CKD in T2D.

Stage 3 kidney disease means that the kidney's function has been cut by half, and most patients experience ancillary problems like high blood pressure or bone difficulties. ‌A survey of 13 studies on stage 3 kidney disease found that the all-cause mortality rate varied from 6% in 3 years to 51% in ten years.

Type 2 diabetes is a leading cause of kidney failure, and if your kidneys fail, you will need dialysis or a kidney transplant to survive. People with kidney disease and type 2 diabetes are three times more likely to die from a heart attack or stroke than patients with type 2 diabetes alone.

Cite this: FDA Approves New Type 2 Diabetes Drug Bexagliflozin - Medscape - Jan 23, 2023.

The latest on diabetes medications The ADA 2023 conference will unveil new findings on medications for type 2 diabetes and obesity, including high-dose oral semaglutide and Lilly's retatrutide, a GIP/GLP-1/glucagon receptor triple agonist.

22, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with chronic kidney disease (CKD ...

Finerenone is FDA-approved1 for those with type 2 diabetes-associated kidney disease who have an eGFR above 25 and a urine-albumin creatinine ratio above 30. It may improve kidney and heart outcomes by preventing fibrosis or scarring of the kidneys.

When diagnosed and managed early, stage 3 CKD has a longer life expectancy than more advanced stages of kidney disease. Estimates can vary based on age and lifestyle. One such estimate says that the average life expectancy is 24 years in men who are 40, and 28 in women of the same age group.

For a 60-year-old man, stage 1 kidney disease life expectancy will be approximately 15 years. That figure falls to 13 years, 8 years, and 6 years in the second, third, and fourth stages of kidney disease respectively.

Your kidneys can't remove extra phosphorus from your blood very well. Too much weakens bones and can damage your blood vessels, eyes, and heart. Meat, dairy, beans, nuts, whole-grain bread, and dark-colored sodas are high in phosphorus. Phosphorus is also added to lots of packaged foods.

Kidney damage may begin 10 to 15 years after diabetes starts. As damage gets worse, the kidneys become worse at cleansing the blood. If the damage gets bad enough, the kidneys can stop working. Kidney damage can't be reversed.